Clinical Trial: An Open-label, Single Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Subjects With Cutaneous Adverse Events Due to Checkpoint Inhibitors

U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07639840) titled 'An Open-label, Single Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Subjects With Cutaneous Adverse Events Due to Checkpoint Inhibitors' on June 05.

Brief Summary: To assess the safety and efficacy of QD 0.3% topical roflumilast foam in patients with cutaneous adverse events due to checkpoint inhibitors over 16 weeks, with or without previous treatment.

Study Start Date: Aug. 01

Study Type: INTERVENTIONAL

Condition: Immune-related Dermatitis

Intervention: DRUG: Roflumilast 0.3% topical foam

QD treatment with roflumilast 0.3% foam

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Massachusetts Gen...